Intec Pharma (NTEC) Earns Daily Coverage Optimism Score of 0.12

Press coverage about Intec Pharma (NASDAQ:NTEC) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intec Pharma earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.8995613420644 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

Shares of Intec Pharma (NTEC) traded up $0.20 on Monday, reaching $7.05. The company had a trading volume of 227,800 shares, compared to its average volume of 275,850. Intec Pharma has a twelve month low of $4.20 and a twelve month high of $9.80.

A number of analysts recently issued reports on NTEC shares. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the stock a “buy” rating in a report on Monday, December 18th. Zacks Investment Research raised Intec Pharma from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Wednesday, November 22nd. Maxim Group set a $8.00 price objective on Intec Pharma and gave the stock a “buy” rating in a report on Friday, November 17th. Finally, CIBC reissued an “outperform” rating and set a $15.00 price objective (up previously from $10.00) on shares of Intec Pharma in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.15.

ILLEGAL ACTIVITY NOTICE: “Intec Pharma (NTEC) Earns Daily Coverage Optimism Score of 0.12” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/08/intec-pharma-ntec-earns-daily-coverage-optimism-score-of-0-12.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Insider Buying and Selling by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit